Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Tax Provisions (2022 - 2024)

Historic Tax Provisions for Zentalis Pharmaceuticals (ZNTL) over the last 3 years, with Q4 2024 value amounting to -$205000.0.

  • Zentalis Pharmaceuticals' Tax Provisions fell 5185.19% to -$205000.0 in Q4 2024 from the same period last year, while for Sep 2025 it was -$205000.0, marking a year-over-year decrease of 18299.6%. This contributed to the annual value of $177000.0 for FY2024, which is 12945.09% up from last year.
  • Zentalis Pharmaceuticals' Tax Provisions amounted to -$205000.0 in Q4 2024, which was down 5185.19% from -$27000.0 recorded in Q3 2024.
  • In the past 5 years, Zentalis Pharmaceuticals' Tax Provisions ranged from a high of $266000.0 in Q2 2024 and a low of -$605000.0 during Q2 2023
  • Its 3-year average for Tax Provisions is -$74416.7, with a median of -$5000.0 in 2022.
  • The largest annual percentage gain for Zentalis Pharmaceuticals' Tax Provisions in the last 5 years was 22727.27% (2023), contrasted with its biggest fall of 365882.35% (2023).
  • Quarter analysis of 3 years shows Zentalis Pharmaceuticals' Tax Provisions stood at -$360000.0 in 2022, then surged by 62.5% to -$135000.0 in 2023, then crashed by 51.85% to -$205000.0 in 2024.
  • Its last three reported values are -$205000.0 in Q4 2024, -$27000.0 for Q3 2024, and $266000.0 during Q2 2024.